The information you provide to the chat will be recorded to improve your experience and to contact you. Please read our privacy notice to see how we are processing and protecting your data. Click to view our Cookie Notice.
We'd love your feedback—take a quick survey to help us improve.
How can we help you today?
Lentivirus (LV) production services
Your trusted partner in LV development and manufacturing
Enter a world of dependable, cutting-edge solutions through our clinical and commercial lentiviral vector manufacturing service.
We’ve manufactured LV for a total of:
590+ total batches
70+ clinical batches
515+ commercial/PPQ batches
We excel in providing high-quality vectors tailored to fulfill your commercial production requirements. Our team has vast experience producing many common lentiviral vector pseudotypes via transient transfection (primarily using HEK293T cell line), an unwavering commitment to high quality standards, and an impeccable track record in manufacturing commercially approved lentiviral vectors. Effortlessly transition from development to large-scale commercial production with our seamlessly scalable manufacturing processes.
What sets us apart:
- Batch excellence: With over 590 batches successfully manufactured, including 70+ clinical batches and 515+ commercial/ PPQ, we have a proven track record of excellence.
- Customized approach: Tailor your lentiviral vectors to match the specific requirements of your commercial applications, ensuring optimal performance.
- Regulatory compliance: Our GMP-compliant manufacturing processes guarantee adherence to regulatory standards, instilling confidence in the approval process.
Our team is experienced in supporting a variety of other viral platforms. For questions about our additional capabilities and capacity, please contact us.
Helpful Resources
Blog
Blog
Viral vector commercialization – Part 1: Tech transfer process for commercial viral vector manufacturing
Learn how tech transfers can help develop and manufacture viral vectors at scale, accelerate vaccine and gene therapy commercialization, and provide expertise.
Blog
Blog
Viral vector commercialization – Part 2: Best practices in process validation lifecycle
Learn more about the robust viral vector process validation cycle, which includes various assessments and studies to ensure the safety, efficacy, and quality of viral vectors.
Article
Article
Strategies to accelerate drug development through harmonization of early and late stage processes
This technical article presents a harmonized and streamlined approach established at Thermo Fisher Scientific for manufacturing AAV and LV vectors for discovery research using technologies and processes mirroring current GMP platforms.
View Article
Webinar
Webinar
Preparing viral vector productions for commercialization
Gene therapy vectors are rapidly approaching the commercial space so commercial readiness is critical for success. Watch our webinar to learn about our capabilities and approaches for preparing viral vectors for commercialization.
View Webinar
Infographic
Infographic
Regulatory pathways for CGT and ATMP products
CGT is one of the world's fastest-growing therapeutic areas today. Instead of treating patients for the rest of their lives, these therapies offer them hope of a cure. In this infographic, we will review three tips for achieving regulatory success.
View Infographic
eBook
eBook
Cell and gene therapies in the US vs. the EU: Top five areas of differentiation
In this eBook we share the five key differences in the drug development and review process for companies hoping to gain market access through US Food and Drug Administration (FDA) or European Medicines Agency (EMA) approval—as well as tips for navigating these differences.
Blog post
A CDMO Partner for every Gene Therapy Manufacturing Stage
Take a closer look at the experiences of NysnoBio and bluebird bio for insight into what companies need in a CDMO partner for every stage of viral vector manufacturing and development.
Fact sheet
Viral vector development and manufacturing services
Thermo Fisher Scientific provides over 20 years of unparalleled experience in developing and manufacturing viral vector products.
Blog post
Tech transfer process for commercial viral vector manufacturing
Learn how tech transfers can help develop and manufacture viral vectors at scale, accelerate vaccine and gene therapy commercialization, and provide expertise.
Blog post
Regulatory support for viral vector commercialization
Learn more about the robust viral vector process validation cycle, which includes various assessments and studies to ensure the safety, efficacy, and quality of viral vectors.
Webinar
Benefits of an integrated approach to gene therapy development and manufacturing
Thermo Fisher Scientific's expert will take you through the development and commercialization of viral vectors for gene therapy, so you can navigate these hurdles and deliver the project in a timely, cost-effective manner. With integrated gene therapy development and manufacturing, you can benefit more than a customized solution. It improves coordination, streamlines decision-making, and uses resources more efficiently.
Article
Strategies to accelerate drug development through harmonization of early and late stage processes
This technical article presents a harmonized and streamlined approach established at Thermo Fisher Scientific for manufacturing AAV and LV vectors for discovery research using technologies and processes mirroring current GMP platforms.
Presentation
Preparing viral vector productions for commercialization
Gene therapy vectors are rapidly approaching the commercial space so commercial readiness is critical for success. Watch our webinar to learn about our capabilities and approaches for preparing viral vectors for commercialization.
Infographic
Regulatory pathways for CGT and ATMP products
CGT is one of the world's fastest-growing therapeutic areas today. Instead of treating patients for the rest of their lives, these therapies offer them hope of a cure.
In this infographic, we will review three tips for achieving regulatory success.
eBook
Cell and gene therapies in the US vs. the EU: Top five areas of differentiation
In this eBook we share the five key differences in the drug development and review process for companies hoping to gain market access through US Food and Drug Administration (FDA) or European Medicines Agency (EMA) approval—as well as tips for navigating these differences.